IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. More Details
+ 2 more risks
Overvalued with concerning outlook.
Share Price & News
How has IMAC Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMAC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: IMAC underperformed the US Healthcare industry which returned 21.2% over the past year.
Return vs Market: IMAC underperformed the US Market which returned 15.8% over the past year.
Price Volatility Vs. Market
How volatile is IMAC Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StWe Think IMAC Holdings (NASDAQ:IMAC) Has A Fair Chunk Of Debt
7 months ago | Simply Wall StSuch Is Life: How IMAC Holdings (NASDAQ:IMAC) Shareholders Saw Their Shares Drop 70%
8 months ago | Simply Wall StDo Directors Own IMAC Holdings, Inc. (NASDAQ:IMAC) Shares?
Is IMAC Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMAC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMAC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMAC is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: IMAC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMAC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMAC is good value based on its PB Ratio (0.9x) compared to the US Healthcare industry average (2.8x).
How is IMAC Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMAC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMAC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMAC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMAC's revenue (16.7% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: IMAC's revenue (16.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMAC's Return on Equity is forecast to be high in 3 years time
How has IMAC Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMAC is currently unprofitable.
Growing Profit Margin: IMAC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMAC is unprofitable, and losses have increased over the past 5 years at a rate of 68% per year.
Accelerating Growth: Unable to compare IMAC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMAC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).
Return on Equity
High ROE: IMAC has a negative Return on Equity (-85.44%), as it is currently unprofitable.
How is IMAC Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IMAC's short term assets ($4.9M) do not cover its short term liabilities ($8.8M).
Long Term Liabilities: IMAC's short term assets ($4.9M) do not cover its long term liabilities ($5.2M).
Debt to Equity History and Analysis
Debt Level: IMAC's debt to equity ratio (73%) is considered high.
Reducing Debt: Insufficient data to determine if IMAC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMAC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IMAC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 41% each year
What is IMAC Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMAC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMAC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMAC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMAC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMAC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jeff Ervin (43 yo)
Mr. Jeffrey S. Ervin, also known as Jeff, has been the Chairman and Director of IMAC Holdings, Inc. since 2018 and serves as its Chief Executive Officer. Mr. Ervin Co-Founded IMAC Holdings in March 2015. M ...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD1.45M) is above average for companies of similar size in the US market ($USD601.03K).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
|Chairman & CEO||no data||US$1.45m||2.5% |
|COO & Director||2.67yrs||US$257.27k||18.17% |
|Independent Director||0.58yr||no data||0.084% |
|Independent Director||1.5yrs||US$134.10k||0.17% |
|Independent Director||1.5yrs||US$134.10k||0.19% |
Experienced Board: IMAC's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IMAC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.8%.
IMAC Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: IMAC Holdings, Inc.
- Ticker: IMAC
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: US$8.821m
- Shares outstanding: 11.84m
- Website: https://www.imacregeneration.com
Number of Employees
- IMAC Holdings, Inc.
- 1605 Westgate Circle
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IMAC||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2019|
|I02||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2019|
IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/29 00:07|
|End of Day Share Price||2020/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.